SOON-SHIONG PATRICK 4
4 · ImmunityBio, Inc. · Filed Feb 12, 2026
Research Summary
AI-generated summary of this filing
ImmunityBio (IBRX) Founder Patrick Soon‑Shiong Receives RSU Shares
What Happened Patrick Soon‑Shiong — Founder, Executive Chairman and Global Chief Scientific & Medical Officer of ImmunityBio (IBRX) and a reported 10% owner — had 274,122 restricted stock units (RSUs) vest on February 10, 2026 and converted those RSUs into common shares. No cash exercise price was required for the conversion (reported at $0.00). To cover tax withholding, 118,560 shares were withheld/treated as disposed at $6.93 per share, yielding approximately $821,621. Net new shares received by Soon‑Shiong were 155,562, worth roughly $1.08 million at the same price; the total market value of the vested RSUs was about $1.90 million.
Key Details
- Transaction date: February 10, 2026; Form 4 filed February 12, 2026 (timely within the typical 2‑business‑day window).
- Primary actions/codes: M = conversion/exercise of derivative (RSUs); F = shares withheld to satisfy tax liability.
- Shares involved: 274,122 RSUs converted; 118,560 shares withheld for taxes at $6.93/share (value $821,621); net issued to insider = 155,562 shares ($1.08M).
- Price basis: Withholding calculated using the issuer’s closing price on Feb 9, 2026 per footnote.
- Shares owned after transaction: not specified in the excerpt provided.
- Footnotes: RSUs represent contingent rights to receive common stock and vest per a schedule (vesting commencement Feb 10, 2025; vesting terms described in footnotes). Reporting person is a 10% owner with potential indirect holdings through multiple affiliated entities (see footnotes regarding NantWorks, NantBio, NantCapital, etc.).
Context This was not an open‑market sale or purchase but a routine RSU vesting and conversion with shares withheld to cover taxes (a common, non‑market cashless withholding). As a 10% owner with holdings through affiliated entities, the filing reflects both personal and affiliated interests; it does not by itself indicate a change in investment view.
Insider Transaction Report
Form 4
SOON-SHIONG PATRICK
DirectorSee remarks10% Owner
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-02-10+274,122→ 29,820,312 total - Tax Payment
Common Stock
[F2]2026-02-10$6.93/sh−118,560$821,621→ 29,701,752 total - Exercise/Conversion
Restricted Stock Units
[F1][F11]2026-02-10−274,122→ 548,246 total→ Common Stock (274,122 underlying)
Holdings
- 246,412,277(indirect: See footnote)
Common Stock
[F3] - 261,705,814(indirect: See footnote)
Common Stock
[F4] - 8,383,414(indirect: See footnote)
Common Stock
[F5] - 7,976,159(indirect: See footnte)
Common Stock
[F6] - 5,618,326(indirect: See footnote)
Common Stock
[F7] - 9,986,920(indirect: See footnote)
Common Stock
[F8] - 47,557,934(indirect: See footnote)
Common Stock
[F9] - 32,606,985(indirect: See footnote)
Common Stock
[F10]
Footnotes (11)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
- [F10]Shares held by NantCancerStemCell, LLC ("NantCancerStemCell"). NantBio is the majority stockholder and an affiliate of NantCancerStemCell and may be deemed to have beneficial ownership of the securities held by NantCancerStemCell. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates.
- [F11]Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.
- [F2]On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld.
- [F3]Shares held by Nant Capital, LLC, an investment vehicle of the reporting person ("Nant Capital").
- [F4]Shares held by Cambridge Equities, LP ("Cambridge Equities"). MP 13 Ventures, LLC ("MP 13 Ventures") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The reporting person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities.
- [F5]Shares held by NantBio, Inc. ("NantBio"). NantWorks, LLC ("NantWorks") is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the shares held by NantBio. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the shares held by NantBio.
- [F6]Shares held by California Capital Equity, LLC ("CalCap"). The reporting person owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap.
- [F7]Shares held by the Chan Soon-Shiong Family Foundation, an exempt corporation organized under the laws of the State of Delaware (the "Foundation"). The Foundation has the sole power to vote and direct the disposition of all shares directly owned by the Foundation, except to the extent it may be deemed to share such power with the reporting person by virtue of the reporting person's control over the Foundation. The reporting person serves as Chairman of the Foundation.
- [F8]Shares held by NantWorks. CalCap directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the securities held by NantWorks. The reporting person directly owns all of the equity interests of CalCap and may be deemed to have voting and dispositive power over the securities held by NantWorks.
- [F9]Shares held by NantMobile, LLC ("NantMobile"). NantWorks is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile.
Signature
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital|2026-02-12